Fusion Antibodies PLC Result of General Meeting & Total Voting Rights (0666N)
15 Mayo 2020 - 4:47AM
UK Regulatory
TIDMFAB
RNS Number : 0666N
Fusion Antibodies PLC
15 May 2020
Fusion Antibodies plc
("Fusion" or the "Company")
Result of General Meeting
Total Voting Rights
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces that all resolutions
put to shareholders at the Company's General Meeting held earlier
today have been passed. As a result, the 1,124,214 Second Placing
Shares being issued pursuant to the Placing announced on 28 April
2020 are expected to be admitted to trading on AIM on 20 May 2020
("Admission") to complete the Placing. Voting at the general
meeting was conducted by way of a poll. The Company will publish
the detailed voting results on its website,
www.fusionantibodies.com, later today.
Total Voting Rights
On Admission, the Company will have 25,424,525 ordinary shares
of 4p each in issue, each with one voting right. There are no
shares held in treasury. Therefore, the Company's total number of
ordinary shares and voting rights is 25,424,525.
The above figure of 25,424,525 may be used by shareholders from
Admission as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same
meaning as in the announcement of 28 April 2020 unless otherwise
defined herein.
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai
Walbrook PR Tel: +44 (0)20 7933 8780
or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx (TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 100 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotechs get to the
clinic faster, with the optimal drug candidate and ultimately speed
up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMFIFSAEEIELII
(END) Dow Jones Newswires
May 15, 2020 05:47 ET (09:47 GMT)
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Fusion Antibodies (LSE:FAB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024